What it does

The gut species most linked to brain and metabolic health are strict anaerobes: they die in a bottle, so no probiotic can carry them. Everyone already has them, and they fade with age. TRI-01 switches them back on.

Three channels

  • Immune. Butyrate trains the gut's immune cells and calms the low-grade inflammation of aging.
  • Metabolic. Two of the four species make propionate by their own route, a signal for blood sugar and metabolic health.
  • Brain. The species make neuroactive signals that travel the gut–brain line. The lead species protects neurons in three published animal models.

The data

In living human gut communities, TRI-01 raised its four target species, the lead neuroprotective species 45-fold in every community tested. The evidence →

Why brands choose it

  • Milligrams. ≤200 mg a day, where classic prebiotics need 5–10 g. Fits a capsule, a stick, a shot.
  • Precision. Four named keystone species, plus the metabolic networks around them.
  • Shelf-stable. A plant-derived small molecule. Nothing alive, no cold chain.
  • Protected. Patent filed, with a favorable EPO opinion on cognitive decline. IP →

The claim path

  • At launch: "supports a healthy gut microbiome."
  • Next: gut health, on our human studies.
  • Then: memory, mental performance and mood in healthy adults.

Regulatory and supply

  • Pathway: US self-affirmed GRAS; Hong Kong for Asia.
  • You receive: CoA per batch, specification sheet, TDS, allergen statement.
  • Process: green, food-grade extraction from upcycled agricultural side-streams.

Formats

Capsules · stick packs · RTD beverages · powders · bars · functional foods.

Request specs & samples See the evidence How it works
Is TRI-01 a probiotic?
No. It contains nothing alive; it switches on species already living in the gut.
What's the dose?
≤200 mg a day, where classic prebiotics need 5–10 g.
What can a brand claim today?
Gut health at launch. Then memory, mental performance and mood in healthy adults, on our clinical studies.
Is it shelf-stable?
Yes — a plant-derived small molecule, no cold chain.
What's the regulatory status?
US self-affirmed GRAS, with Hong Kong for Asia. TRI-04 reaches market first, in 2027.